Register for Updates

Pharmacists

Given the many demands on your time, the following resources have been developed utilising a flexible online format and are designed to facilitate peer-to-peer information exchange about biosimilar medicines – relevant to pharmacy practice.

Also available are the following resources for download and print.

  • Pharmacist Factsheet
  • Healthcare Professional Essentials

To ensure that available materials meet your and your patients’ needs, we invite you to submit your feedback via our dedicated ‘have your say’ area on the biosimilar hub.


Resources

Pharmacist Factsheet
Information on biosimilar medicines
Download Button
This 6 page factsheet provides pharmacists with information on biosimilar medicines.
Healthcare professionals Essentials A4
Essential information on biosimilar medicines
Download Button
This document provides healthcare professionals with the essentials on biosimilar medicines.
Healthcare professional Essentials DL
Essential information on biosimilar medicines
Download Button
This DL sized brochure has been designed to wrap around other leaflets, brochures or folders.
Consumer/carer Factsheet
Information on biosimilar medicines
Download Button
This factsheet provides consumers and carers with information on biosimilar medicines.
Consumer/carer Essentials A4
Essential information on biosimilar medicines
Download Button
This document provides consumers and carers with the essentials on biosimilar medicines.
Consumer/carer Essentials DL
ESSENTIAL INFORMATION ON BIOSIMILAR MEDICINES
Download Button
This DL sized brochure has been designed to wrap around other A4 leaflets, brochures or folders.
Patient letter template
Supporting documentation to inform patients of a switch to a biosimilar medicine
Download Button
A letter template that you may wish to use to inform patients of a brand change.

Information on biosimilar medicines

Biosimilar medicines
a highly similar version of an already registered biological medicine
Biological medicines are pharmaceutical products that contain one or more active substances that are derived from living cells or organisms.
How similar is Biosimilar?
Demonstrating high similarity is the foundation of development
As biosimilar medicines are designed and engineered using the latest technology to resemble their reference product as closely as possible,
Development of biological medicines
BIOLOGICAL MEDICINES ARE MEDICINES THAT ARE MADE BY LIVING CELLS OR ORGANISMS
Biological medicines are medicines that are made by living cells or organisms. They are usually made of large proteins that are naturally produced in the human body.
Development of biosimilar medicines
Biosimilar medicines are used to treat the same diseases in the same way
A biosimilar medicine is a highly similar version of an original brand of a biological medicine, brought to market by a different manufacturer once the patent on the original brand expires.
Reassurance of similarity
The aim of the clinical program is to confirm therapeutic equivalence
Biosimilar medicines are required to undergo a tailored clinical program. This is normally a stepwise process, beginning with pharmacokinetic/ pharmacodynamic (PK/PD) studies.
Regulatory framework
The TGA approved its first biosimilar medicine in 2010
More than a decade of international real-world experience and associated post-marketing data has found no difference in the safety or health outcomes of patients.
Approval of biological medicines
Australia has a strong regulatory system for all medicines
Australia has a strong regulatory system that ensures the safety, effectiveness and quality of all medicines, including biological medicines.

Videos

Barry Jenkins
pharmacist
Barry has enjoyed a diverse career beginning in community pharmacy and moving into regional and remote hospital pharmacy in WA and far North QLD.
David Ford
Pharmacist
Executive Director Pharmacy and Redevelopment, North East Health, and owner and Director, David Ford Healthcare Consulting.
A/Professor Michael Ward
APP2019: Biosimilar Update
A/Prof Ward continues to practice as a pharmacist and has research interests broadly related to the factors that influence variability in the safety and efficacy of medicines.
David Ford
Pharmacy Connect 2018: Biologics and biosimilars
David Ford is a proven hospital executive with 30 years of clinical and management experience in hospital administration and department directorship.
Dr Paul Cornes, UK Oncologist
APP2018: Biosimilar medicines – the case for change
Dr Cornes is an oncologist in Bristol. He is part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment.

Courses

Accredited CPD activity for pharmacists on biosimilar medicines
Read more